Mineralys Therapeutics MLYS is set to give its latest quarterly earnings report on Monday, 2024-11-11. Here's what investors need to know before the announcement.
Analysts estimate that Mineralys Therapeutics will report an earnings per share (EPS) of $-0.83.
Anticipation surrounds Mineralys Therapeutics's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
Earnings History Snapshot
Last quarter the company missed EPS by $0.13, which was followed by a 22.82% drop in the share price the next day.
Here's a look at Mineralys Therapeutics's past performance and the resulting price change:
| Quarter | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| EPS Estimate | -0.70 | -0.67 | -0.82 | -0.76 |
| EPS Actual | -0.83 | -0.70 | -0.61 | -0.57 |
| Price Change % | -23.0% | -5.0% | -2.0% | -7.000000000000001% |
Performance of Mineralys Therapeutics Shares
Shares of Mineralys Therapeutics were trading at $14.16 as of November 07. Over the last 52-week period, shares are up 124.06%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
To track all earnings releases for Mineralys Therapeutics visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
